Breast Cancer, Head and Neck Cancer, Lung Cancer, Ovary Cancer, Renal Cell Carcinoma Metastatic, Stomach Cancer, Thyroid Cancer
Conditions
Brief summary
The purpose of the CAPABLE study is to compare health-related quality of life in renal cell carcinoma patients who use or do not use a mobile-based application to monitor adverse events for cancer treatment at home. As secondary objectives, the study investigates the usability of the system and its generalizability to other cancer types
Detailed description
The study is designed as a prospectively enrolling, quasi-experimental cohort study in cancer patients, eligible for systemic treatment. The CAPABLE cohort will receive the smartphone application and a multi-sensorial smartwatch (ASUS VivoWatch 5 HC-B05). Patients will be asked to use the system for at least 6 months after enrollment. If, after 6 months, a patient wants to keep using the system, he will be allowed to do so, until the end of the study. Questionnaires on health-related quality of life will be administered to the patients on baseline (T0) and every three months (T1 and T2). Lost to follow-up data will be included in intention-to-treat analysis. Qualitative and quantitative user experience studies will be done at enrollment, after 3 months and at the end of the follow-up period with the CAPABLE system. Results of this interventional study will be compared with a control cohort consisting of renal cell carcinoma patients, recruited in 2021 with the same inclusion criteria as this study population, but receiving standard care (ICSM CE number 2546, dated 13/04/2021 and amended on 09/02/2022).
Interventions
DEVICECAPABLE cohort
The CAPABLE cohort receives the mobileapplication and a multi-sensorial smartwatch (ASUS VivoWatch 5 HC-B05). Patients will be asked to use the system for at least 6 months. The CAPABLE app serves three main functionalities for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing
Sponsors
University of Pavia
Policlinico di Bari Ospedale Giovanni Paolo XXIII
Biomeris srl
The Netherlands Cancer Institute NKI
University of Haifa
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
IBM Research
Bitsens JSC
Poznań University of Technology
Deontics LTD
Associazione Italiana Malati di Cancro AIMAC
Universidad Politecnica de Madrid
Istituti Clinici Scientifici Maugeri SpA
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults (age \>=18 years) * Sufficient understanding of the Italian language * Patients or their caregiver (upon patient's consent) can use a smartphone * Histologically or cytologically confirmed diagnosis of RCC, lung, breast, thyroid o head and neck cancer * Candidate to systemic treatment (targeted agents, immune checkpoint inhibitors, or a combination of the two) * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at the start of the treatment.
Exclusion criteria
* Recruitment and consent denial * Not able of understanding and complying with the protocol requirements (including basic technological abilities) * Given the fact that each subject involved in the clinical study must be able to understand and sign the informed consent presented by the researcher, lack of this capability represents a specific exclusion criterion in the study protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in health-related QoL outcomes in RCC patients | 6 months after the enrollment | The primary objective of this study is to investigate whether HRQoL of RCC patients eligible for systemic treatment can be improved by a patient-centred mobile coaching- and monitoring system |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| User experience of the CAPABLE system in RCC patients | 6 months after the enrollment | This study will gather qualitative and quantitative information to quantify usefulness, easiness, acceptability and feasibility of the end users' solutions. The patient app will be assessed also in terms of perceived impact and support derived from the digital technologies. The health professional web application will be evaluated to understand to what extent this can be integrated and adopted in the clinical practice |
| User experience of the CAPABLE system in other cancer types patients | 6 months after the enrollment | To evaluate the generalizability of the system on other cancer types, the user experience study is performed also on patients with cancer types different from RCC (e.g Breast, Ovary, Head&Neck cancer). The patient app will be assessed also in terms of perceived impact and support derived from the digital technologies. The health professional web application will be evaluated to understand to what extent this can be integrated and adopted in the clinical practice |
Countries
Italy
Outcome results
None listed